WHO WE ARE

DELIVERING
THE PROMISE
OF TARGETED
GENE SILENCING MEDICINES

NanoGenics is a leading siRNA therapeutics company.

We are committed to developing cutting-edge gene silencing medicines using our proprietary gene delivery technology, LipTide.

Read more about who we are...

OUR PRODUCTS

Our lead product, ECP-102, addresses the urgent need to make the mainstay of cancer treatment, chemotherapy, more effective.

Looking forward, we aim to enhance the activity of new targeted therapies through synergistic combinations with ECP-102.

Our lead products will be in the clinic in 2021, aimed at meeting the most pressing needs in oncology and ophthalmology.

 

 

 

Image
Image

Our Delivery

LipTide is a revolutionary peptide nanoscale delivery vehicle invented to mimic a natural virus for targeted delivery of siRNA into cells.

With appealing clinical properties, the capability to deliver genetic material to almost any cell type, low toxicity, and repeat dosing, the LipTide technology represents new promise across several therapeutic areas of unmet need.


Read more about what we do...

Image

OUR TEAM

Our unique team of experts brings together

experience, passion and expertise from bench to bedside.


Read more about our team...
Image

Contact Us

Get in touch to learn more about how we are taking our products from concept to clinic.

Dr Simon Newman
Chief Scientific Officer
+44 (0) 7714 041 487
simon.newman@nanogenics.co.uk


Image
Image

Dr Alan Walker
Chief Executive Officer
+44 (0) 7590 259 941
alan.walker@nanogenics.co.uk


Image
Image